p53 dry gene powder enhances anti-cancer effects of chemotherapy against malignant pleural mesothelioma

Gene Ther. 2024 Mar;31(3-4):119-127. doi: 10.1038/s41434-023-00424-y. Epub 2023 Oct 13.

Abstract

Dry gene powder is a novel non-viral gene-delivery system, which is inhalable with high gene expression. Previously, we showed that the transfection of p16INK4a or TP53 by dry gene powder resulted in growth inhibitions of lung cancer and malignant pleural mesothelioma (MPM) in vitro and in vivo. Here, we report that dry gene powder containing p53- expression-plasmid DNA enhanced the therapeutic effects of cisplatin (CDDP) against MPM even in the presence of endogenous p53. Furthermore, our results indicated that the safe transfection with a higher plasmid DNA (pDNA) concentration suppressed MPM growth independently of chemotherapeutic agents. To develop a new therapeutic alternative for MPM patients without safety concerns over "vector doses", our in vitro data provide basic understandings for dry gene powder.

MeSH terms

  • Cell Line, Tumor
  • Cisplatin / metabolism
  • Cisplatin / pharmacology
  • Cisplatin / therapeutic use
  • DNA
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mesothelioma* / drug therapy
  • Mesothelioma* / genetics
  • Mesothelioma, Malignant*
  • Pleural Neoplasms* / drug therapy
  • Pleural Neoplasms* / genetics
  • Powders / therapeutic use
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Powders
  • Tumor Suppressor Protein p53
  • Cisplatin
  • DNA